Kelsy Ketchum

The researchers used the CellSearch assay to measure circulating tumor cells and determine the response to certain treatments as well as survival outcomes.

The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.

The test assigns a pancreatic cancer subtype based on the expression of 16 genes measured using an array.

The plan, announced in January, would reclassify many Class III in vitro diagnostic devices as Class II, impacting companion diagnostic and infectious disease tests.

The firm hopes to generate more validation data with partners on the ability of its latest RNA sequencing test to guide treatment for patients with solid tumors.

The Northstar Select comprehensive genomic profiling test uses BillionToOne's proprietary Quantitative Counting Template technology for solid tumors.

The researchers utilized an existing computational tool and customized it to select patients with microsatellite instability for further testing.

The researchers built on prior work on a prognostic model of overall survival that relied only on clinical factors.

The AI assistant has been trained on a knowledgebase made up of the latest Clinical Pharmacogenetics Implementation Consortium data for statins.

The test detects blood gene expression biomarkers that are predictive of high hallucination and high delusion states and future hospitalizations.